Clinical Trials Browser

Phase 3 × neratinib × Clear all

NCT05760612 2025-09-25

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Phase 3 Recruiting

Breast Neoplasms

NCT05615818 2025-04-23

SAFIR-ABC10

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT00878709 2021-06-11

ExteNET

Phase 3 Completed

2,840 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT01808573 2021-06-11

NALA

Phase 3 Completed

621 enrolled 21 charts 2 FDA

HER2+ Metastatic Breast Cancer (MBC)